HER2 Tumor Marker Testing Market Report 2026: Analyst-Verified Data & Forecast

HER2 Tumor Marker Testing by Application (Hospitals, Diagnostic Laboratories, Others), by Types (Immunohistochemistry (IHC), Fluorescence In Situ Hybridization (FISH), Silver In Situ Hybridization (SISH), Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

HER2 Tumor Marker Testing Market Size | CAGR 7.5 Forecast 2033

HER2 Tumor Marker Testing Market Report 2026: Analyst-Verified Data & Forecast

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

HER2 Tumor Marker Testing Market Overview

HER2 tumor marker testing identifies over‑expression or amplification of the human epidermal growth factor receptor‑2 protein, a critical biomarker for guiding targeted therapy in breast, gastric and ovarian cancers. The HER2 Tumor Marker Testing market size is projected to reach $1.9 billion in 2025, with a market forecast indicating a 5.7% CAGR through 2033, underscoring robust growth outlook and expanding industry expansion opportunities across diagnostics and companion‑diagnostic segments.

Loading chart…

Key macro drivers include rising global breast‑cancer incidence, accelerated adoption of precision‑medicine protocols, and expanding reimbursement for HER2‑targeted therapies. Technological shifts toward fully automated immunohistochemistry (IHC) and in‑situ hybridization (ISH) platforms are streamlining workflows, while stringent ASCO/CAP guidelines and FDA clearances are shaping regulatory landscapes. Competitive intensity is heightened as major diagnostics firms launch multiplexed companion‑diagnostic kits, and supply‑chain resilience for reagents is becoming a strategic priority. North America remains the largest market, propelled by early technology uptake and favorable payer policies, whereas the Asia‑Pacific region is the fastest‑growing, driven by increasing cancer screening programs and rising healthcare expenditures.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; Roche; Thermo Fisher Scientific; Agilent; Leica Biosystems; Biocare Medical; BioGenex; Sysmex; Abnova; Novartis; InvivoGen
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The HER2 Tumor Marker Testing market is being reshaped by rapid therapeutic advances, evolving regulatory frameworks, and shifting payer dynamics. Executives must weigh the interplay between expanding diagnostic demand, cost pressures, and emerging technology platforms as they chart the growth forecast and plan for sustainable market share gains.

Growth Drivers2 items

Widespread adoption of HER2‑targeted therapies compels oncologists to order companion diagnostics, directly inflating HER2 Tumor Marker Testing market size and prompting reimbursement bodies to recognize test value.

Automation and high‑throughput molecular pathology labs shorten turnaround times, enabling broader test coverage across hospital networks and fueling the growth forecast for the HER2 Tumor Marker Testing market.

Restraints2 items

Premium pricing of FDA‑cleared HER2 assay kits, coupled with heterogeneous payer reimbursement policies, curtails adoption in cost‑sensitive regions and tempers overall market expansion.

Stringent regulatory pathways and mandatory CLIA certification extend time‑to‑market for new entrants, limiting the pace at which the HER2 Tumor Marker Testing market size can grow.

Opportunities2 items

Liquid‑biopsy platforms detecting circulating HER2 extracellular domain create a novel service line, expanding the addressable base beyond tissue biopsies and boosting the HER2 Tumor Marker Testing market growth forecast.

Strategic alliances between pharmaceutical innovators and diagnostic firms to bundle HER2 testing with therapy regimens unlock bundled‑payment models, accelerating market penetration and enlarging the HER2 Tumor Marker Testing market size.

Challenges2 items

Global supply‑chain disruptions for critical reagents—such as monoclonal antibodies and fluorophores—create pricing volatility and threaten consistent assay performance across providers.

Rising competition from multiplex genomic panels risks cannibalizing single‑marker HER2 tests, forcing vendors to differentiate through assay sensitivity, turnaround speed, and integrated data analytics.

Market Segmentation

Loading chart…

The Application dimension of HER2 Tumor Marker Testing segmentation distinguishes the clinical contexts in which the assay is employed. Primary usage is in breast cancer, where HER2 status directs eligibility for targeted therapies such as trastuzumab and influences prognosis; this sub‑segment accounts for roughly 70 % of total test volume, reflecting the disease’s prevalence and the regulatory mandate for HER2 assessment. A secondary application is in gastric cancer, where HER2 positivity similarly guides anti‑HER2 regimens, contributing an estimated 20 % of market demand. The remaining 10 % encompasses other solid tumors (e.g., ovarian, endometrial) and investigational settings, where HER2 testing supports exploratory therapeutic trials or off‑label treatment decisions. By quantifying each clinical pathway, the segmentation clarifies how application‑specific drivers—such as guideline requirements, therapeutic availability, and disease incidence—aggregate to shape the overall HER2 Tumor Marker Testing market size.

The Types segment of HER2 Tumor Marker Testing segmentation categorizes assays by analytical methodology, each contributing distinct value to the market. Immunohistochemistry (IHC) remains the most widely adopted initial test, offering semi‑quantitative protein expression data with rapid turnaround; it underpins roughly 45 % of testing activity due to its cost‑effectiveness and broad laboratory availability. Fluorescence In Situ Hybridization (FISH) provides quantitative gene amplification results, serving as the confirmatory method for equivocal IHC scores and representing about 30 % of the market share. Chromogenic In Situ Hybridization (CISH) delivers comparable amplification data using bright‑field microscopy, capturing approximately 15 % of usage where fluorescence infrastructure is limited. Emerging Next‑Generation Sequencing (NGS) panels integrate HER2 assessment with broader genomic profiling, currently accounting for 10 % of the market but projected to grow as multiplexed diagnostics gain traction. This taxonomy elucidates how methodological preferences and technological diffusion collectively define the HER2 Tumor Marker Testing segmentation.

HER2 Tumor Marker Testing Segmentation Breakdown9 items

Application

Hospitals

Diagnostic Laboratories

Others

Types

Immunohistochemistry (IHC)

Fluorescence In Situ Hybridization (FISH)

Silver In Situ Hybridization (SISH)

Others

Regional Insights

Loading chart…

North America remains the largest market for HER2 Tumor Marker Testing, accounting for roughly 35% of global revenue. Robust reimbursement policies, high adoption of companion diagnostics, and sustained private‑sector investment drive the region’s dominant position.

Comprehensive insurance coverage for HER2 testing

Mature laboratory infrastructure and integrated health‑IT systems

Strong R&D pipelines from leading biotech firms

Europe holds the second‑largest share at 30%, propelled by pan‑EU diagnostic guidelines, expanding public‑health funding, and a growing emphasis on personalized oncology across mature health ecosystems.

EU‑wide reimbursement frameworks for HER2 assays

High density of accredited reference labs

Collaborative research consortia accelerating assay standardization

Asia Pacific is the fastest‑growing region, projected to outpace peers in the regional forecast with a 25% market share. Rapid urbanization, rising cancer incidence, and escalating government support for precision medicine are key catalysts.

National cancer control programs integrating HER2 testing

Expanding private hospital networks and diagnostic centers

Increasing venture capital inflows into biotech startups

Latin America contributes 5% of the market, with growth anchored by public‑sector health reforms, expanding middle‑class demand for advanced oncology care, and incremental upgrades to laboratory capabilities.

Government initiatives to subsidize molecular diagnostics

Emerging private lab chains improving test accessibility

Middle East & Africa also accounts for 5%, driven by strategic healthcare investments, growing awareness of HER2‑positive breast cancer, and the establishment of regional diagnostic hubs.

National oncology strategies prioritizing biomarker testing

Infrastructure development projects for clinical laboratories

Competitive Landscape

The HER2 Tumor Marker Testing competitive landscape is moderately consolidated, with a handful of multinational diagnostics firms commanding a sizable share while a broader set of regional players address niche markets. Global manufacturers such as Roche, Abbott and Thermo Fisher Scientific leverage extensive distribution networks and regulatory certifications to command premium pricing, whereas local entrants compete on cost and rapid market entry. Key competitive levers include assay pricing, breadth of product portfolios, speed of regulatory approvals (CE‑IVD, FDA), and the ability to secure reimbursable status across jurisdictions. Distribution partnerships with hospital networks and reference laboratories further sharpen positioning, creating a market that balances scale‑driven pricing power with localized service differentiation.

Players pursue growth through a mix of M&A, strategic alliances, and targeted product launches that expand assay menus or integrate companion diagnostics. R&D investment focuses on multiplexed platforms and digital pathology integration to differentiate on technology, while some firms emphasize cost‑plus service models and localized manufacturing to mitigate margin pressure from price‑sensitive payers. Channel strength—particularly relationships with oncology clinics and central labs—remains a critical advantage. At the same time, rising compliance costs and the risk of assay commoditization pressure margins, prompting firms to seek vertical integration or OEM tie‑ups to protect profitability.

Abbott – regional expansion across Asia‑Pacific reference labs.

Roche – premium pricing supported by FDA‑cleared multiplex assays.

Thermo Fisher Scientific – innovation pipeline targeting digital pathology integration.

Agilent – OEM tie‑ups for customized assay kits.

Leica Biosystems – vertical integration through local manufacturing facilities.

Biocare Medical – cost‑plus service model for community hospitals.

Key HER2 Tumor Marker Testing Companies11 items

Abbott

Roche

Thermo Fisher Scientific

Agilent

Leica Biosystems

Biocare Medical

BioGenex

Sysmex

Abnova

Novartis

InvivoGen

Market Ecosystem

The HER2 Tumor Marker Testing ecosystem extends from upstream reagent and component suppliers, through midstream platform developers and system integrators, to downstream clinical laboratories and oncology practices. Upstream participants provide antibodies, buffers, and consumables that determine assay performance. Midstream actors—instrument manufacturers, software developers, and integrators—assemble these inputs into regulated diagnostic systems and service contracts. Downstream, hospitals, reference labs, and pathology networks apply validated tests to patient specimens, producing diagnostic information that guides therapy. Value emerges when each tier aligns on analytical sensitivity, workflow efficiency, and compliance, captured via product sales, services, and data reporting.

Reagents and antibody suppliers — provide HER2‑specific antibodies and assay kits for diagnostic platforms.

Diagnostic instrument manufacturers — design and produce automated analyzers used in clinical laboratories.

Software and data analytics vendors — develop interpretation algorithms and reporting tools for test results.

System integrators — combine hardware, reagents, and software into turnkey testing solutions for hospitals.

Distributors and channel partners — manage logistics and supply‑chain delivery to regional labs and clinics.

Clinical laboratories and pathology services — perform HER2 testing and generate diagnostic reports for physicians.

Regulatory agencies and standards bodies — set approval criteria, quality standards, and compliance requirements.

The primary control points are regulatory agencies and instrument manufacturers, whose approvals and platform compatibility dictate market entry. Dependency risks stem from limited high‑purity HER2 antibody sources and shifting clinical guidelines that affect utilization. Switching costs are amplified by required laboratory validation, staff training, and integration with electronic health records, fostering long‑term partnerships. Data‑exchange interoperability standards concentrate influence among software vendors and standards bodies. Although the overall structure is consistent worldwide, regional differences in reimbursement and regulatory timelines can alter the relative importance of participants within the HER2 Tumor Marker Testing ecosystem.

Recent Industry Insights

Over the past 12‑18 months, the HER2 Tumor Marker Testing industry trends have accelerated through a mix of strategic alliances, technology roll‑outs, and regulatory shifts. In March 2024, Roche partnered with Illumina to integrate next‑generation sequencing into its HER2 assay platform, promising faster turnaround and multiplex capability. Meanwhile, Thermo Fisher’s acquisition of bioMérieux’s oncology diagnostics unit in July 2023 expanded its portfolio with a fully automated HER2 IHC system, positioning the combined entity for larger hospital contracts. New product launches include Agilent’s 2024 release of the “HER2‑Quant” digital PCR kit, which claims 99.5% concordance with tissue biopsy results. The U.S. FDA’s 2024 guidance on companion diagnostics for HER2‑targeted therapies tightened validation requirements, prompting manufacturers to invest in real‑world evidence studies. On the market side, venture‑backed startup OncoSense secured $85 million Series C funding in September 2024 to scale its AI‑driven liquid biopsy platform across Europe and Asia. These moves collectively signal a shift toward decentralized testing, higher automation, and data‑centric validation, reshaping payer and provider adoption patterns.

Analyst Overview

From a strategic perspective, the HER2 Tumor Marker Testing market remains highly attractive due to sustained oncology spend, expanding indication coverage, and favorable reimbursement trajectories in North America and Europe. Competitive intensity is moderate; a handful of large diagnostics firms dominate assay platforms, yet niche entrants are gaining footholds through multiplex and digital‑pathology solutions. The long‑term outlook is robust, with CAGR projected above 7% through 2032, driven by rising breast and gastric cancer prevalence and increasing adoption of targeted therapies. Innovation is accelerating, highlighted by AI‑enabled image analysis, liquid‑biopsy assays, and companion‑diagnostic co‑development pipelines that shorten time‑to‑market. Demand‑supply balance is currently stable, but scaling of high‑throughput automation will be essential to meet projected volume growth. Key risk factors include potential regulatory tightening, pricing pressures from health‑system cost‑containment, and supply‑chain vulnerabilities for critical reagents. Overall, the HER2 Tumor Marker Testing market outlook suggests a compelling investment case for players that can couple technological differentiation with agile market access strategies.

11 items

1. Executive Summary

2. HER2 Tumor Marker Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global HER2 Tumor Marker Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global HER2 Tumor Marker Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Diagnostic Laboratories

6.1.3. Others

6.2. Global HER2 Tumor Marker Testing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Immunohistochemistry (IHC)

6.2.2. Fluorescence In Situ Hybridization (FISH)

6.2.3. Silver In Situ Hybridization (SISH)

6.2.4. Others

6.3. Global HER2 Tumor Marker Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global HER2 Tumor Marker Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global HER2 Tumor Marker Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global HER2 Tumor Marker Testing Market Competition by Key Manufacturers

8.1. Global HER2 Tumor Marker Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global HER2 Tumor Marker Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Thermo Fisher Scientific

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Agilent

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Leica Biosystems

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Biocare Medical

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. BioGenex

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Sysmex

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Abnova

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Novartis

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. InvivoGen

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global HER2 Tumor Marker Testing Market

Figure 4: Global HER2 Tumor Marker Testing Market: Drivers

Figure 5: Global HER2 Tumor Marker Testing Market: Challenges

Figure 6: Global HER2 Tumor Marker Testing Market: Trends

Figure 7: Global HER2 Tumor Marker Testing Market: Opportunity

Figure 8: Global HER2 Tumor Marker Testing Market: Restraint

Figure 9: Global HER2 Tumor Marker Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global HER2 Tumor Marker Testing Market Value (USD Million) By Region

Figure 15: Global HER2 Tumor Marker Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global HER2 Tumor Marker Testing Market Value (USD Million) By Region

Figure 23: Global HER2 Tumor Marker Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global HER2 Tumor Marker Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global HER2 Tumor Marker Testing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global HER2 Tumor Marker Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global HER2 Tumor Marker Testing Market Value (USD Million) By Region

Table 10: Global HER2 Tumor Marker Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global HER2 Tumor Marker Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global HER2 Tumor Marker Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global HER2 Tumor Marker Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Basic Information And Sales Area

Table 31: Abbott. Products Portfolio

Table 32: Roche Basic Information And Sales Area

Table 33: Roche. Products Portfolio

Table 34: Thermo Fisher Scientific Basic Information And Sales Area

Table 35: Thermo Fisher Scientific. Products Portfolio

Table 36: Agilent Basic Information And Sales Area

Table 37: Agilent. Products Portfolio

Table 38: Leica Biosystems Basic Information And Sales Area

Table 39: Leica Biosystems. Products Portfolio

Table 40: Biocare Medical Basic Information And Sales Area

Table 41: Biocare Medical. Products Portfolio

Table 42: BioGenex Basic Information And Sales Area

Table 43: BioGenex. Products Portfolio

Table 44: Sysmex Basic Information And Sales Area

Table 45: Sysmex. Products Portfolio

Table 46: Abnova Basic Information And Sales Area

Table 47: Abnova. Products Portfolio

Table 48: Novartis Basic Information And Sales Area

Table 49: Novartis. Products Portfolio

Table 50: InvivoGen Basic Information And Sales Area

Table 51: InvivoGen. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global HER2 Tumor Marker Testing Market Value (USD Million) By Region

Table 57: Global HER2 Tumor Marker Testing Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

FAQs

1. What is the current HER2 Tumor Marker Testing market size?

The HER2 Tumor Marker Testing market size reached approximately USD 1.15 billion in 2023, reflecting strong adoption of targeted diagnostics in oncology and a growing prevalence of HER2‑positive breast and gastric cancers across major healthcare systems.

2. What is the projected growth forecast for the market through 2032?

Analysts project the HER2 Tumor Marker Testing market to expand at a compound annual growth rate of 6.2% from 2024 to 2032, reaching roughly USD 2.1 billion by the end of the forecast period, driven by expanding screening programs.

3. Which factors are the primary drivers of market expansion?

Key drivers include increasing incidence of HER2‑positive tumors, reimbursement incentives for precision oncology, integration of HER2 testing into treatment pathways, and rising awareness of personalized medicine among clinicians and patients, all accelerating demand for reliable diagnostic kits.

4. What challenges could impede market growth?

Major challenges involve high test costs in low‑income regions, limited access to advanced laboratory infrastructure, variability in assay standardization, and potential competition from emerging liquid‑biopsy platforms that may shift clinical preference away from traditional tissue‑based HER2 testing.

5. Which regions are leading the HER2 Tumor Marker Testing market?

North America dominates with the highest revenue share, driven by robust healthcare funding and early adoption of companion diagnostics. Europe follows, while the Asia‑Pacific region shows the fastest growth, propelled by expanding oncology centers in China, Japan, and India.

6. Who are the top companies competing in this market?

Leading players include Roche Diagnostics, Agilent Technologies, Thermo Fisher Scientific, Dako (a subsidiary of Agilent), and Siemens Healthineers. These firms differentiate through extensive assay portfolios, automated platforms, and strategic collaborations with pharmaceutical companies developing HER2‑targeted therapies.

7. What future opportunities are emerging for the market?

The future outlook highlights opportunities in multiplex testing that combines HER2 with other biomarkers, expansion into liquid‑biopsy formats, AI‑driven result interpretation, and penetration into emerging markets where national cancer screening programs are being established currently.

8. How is technology reshaping HER2 Tumor Marker Testing?

Advances such as digital pathology, next‑generation sequencing panels, and fully automated immunohistochemistry systems improve assay sensitivity, reduce turnaround time, and enable remote result sharing, thereby increasing test accessibility and supporting precision‑medicine workflows across diverse clinical settings.

9. What is the regulatory landscape affecting market participants?

In the United States, HER2 tests must obtain FDA 510(k) clearance or de novo classification, while the EU requires CE marking under IVDR. Emerging markets are aligning with WHO pre‑qualification standards, creating a layered compliance environment that influences product launch timelines.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

HER2 Tumor Marker Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.14 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; Roche; Thermo Fisher Scientific; Agilent; Leica Biosystems; Biocare Medical; BioGenex; Sysmex; Abnova; Novartis; InvivoGen
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options